Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY19 results · Jul–Sep 2018
Astec LifeSciences reported revenue from operations of ₹112.72 crore and net profit of ₹11.57 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.72 | — | — | 65.47 | +72.2% |
| Other income | 1.85 | — | — | 0.02 | 103x |
| Total income | 114.57 | — | — | 65.49 | +74.9% |
| Profit before tax | 17.91 | — | — | 2.45 | +631.7% |
| Net profit for the period | 11.57 | — | — | 1.49 | +679.1% |
| EPS, basic (₹) | 5.92 | — | — | 0.08 | 74x |
| Net margin (%) | 10.3 | — | 2.3 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.72 | — | — | 65.47 | +72.2% |
| Other income | 1.85 | — | — | 0.02 | 103x |
| Total income | 114.57 | — | — | 65.49 | +74.9% |
| Profit before tax | 17.90 | — | — | 2.43 | +635.7% |
| Net profit for the period | 11.57 | — | — | 1.48 | +683.4% |
| EPS, basic (₹) | 5.92 | — | — | 0.08 | 74x |
| Net margin (%) | 10.3 | — | 2.3 |
Consolidated
- Filed with BSE
- 30 Oct 2018, 14:25 IST
- Board meeting
- 26 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2018, 14:25 IST
- Board meeting
- 26 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE